As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
12 Analysts have issued a Oculis forecast:
12 Analysts have issued a Oculis forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -61 -61 |
43%
43%
|
|
EBITDA | -96 -96 |
52%
52%
|
EBIT (Operating Income) EBIT | -97 -97 |
52%
52%
|
Net Profit | -128 -128 |
75%
75%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
Head office | Switzerland |
CEO | Riad Sherif |
Employees | 49 |
Founded | 2016 |
Website | oculis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.